Hims & Hers

forhims.com →

+8%

est. 2Y upside i

Healthcare

Telehealth platform providing online health and wellness services

Rank

#2474

Sector

Telehealth

Est. Liquidity

~2Y

Data Quality

Data: High

Hims & Hers presents a moderate upside opportunity for a job seeker, driven by its strong historical revenue growth (59% in 2025) and recent profitability ($128M net income).

Last updated: March 10, 2026

Bull (31%)+100%

Hims & Hers successfully navigates the transition to branded GLP-1 offerings, leveraging the Novo Nordisk partnership to expand market share and mitigate margin impact through scale and new product launches. Continued strong subscriber growth and expansion into new international markets drive revenue to over $4.5 billion by 2028, justifying a $7.4 billion valuation (2x current) as the company solidifies its position as a leading consumer telehealth platform.

Base (42%)+40%

Hims & Hers maintains its market position in core segments, achieving its projected 15-24% YoY revenue growth in 2026, reaching approximately $2.8 billion. The partnership with Novo Nordisk stabilizes the GLP-1 business, but margin pressure from branded drugs limits significant multiple expansion. The company achieves a valuation of approximately $5.18 billion, reflecting steady execution and moderate market appreciation.

Bear (27%)-40%

The shift to branded GLP-1 drugs leads to greater-than-expected margin compression, and intense competition in other segments erodes pricing power. Regulatory pressures or renewed legal challenges (Novo Nordisk reserves the right to refile) further impact investor confidence, causing growth to stall below 15% and the valuation to decline to approximately $2.22 billion, resulting in a significant loss of equity value.

Est. time to liquidity~2.0 years
Adjusted for competitive dynamics: 47% (raw: 8%, adjustment: +10%)

Preference Stack Risk

high

The company has raised approximately $1.477 billion in total capital (VC, SPAC proceeds, and convertible notes) against a current valuation of $3.7 billion.

Dilution Risk

high

The $1 billion in convertible senior notes due 2030 represents a significant source of potential future dilution for common shareholders upon conversion.

Secondary Liquidity

active

As a publicly traded company on the NYSE (HIMS), shares are actively traded on the open market, providing immediate liquidity.

Questions to Ask at the Interview

Strategic questions based on Hims & Hers's data — designed to show you've done your homework.

  • 1

    “How is Hims & Hers planning to mitigate the potential margin impact from shifting from compounded GLP-1s to branded, FDA-approved medications, and what strategies are in place to ensure continued profitability?”

  • 2

    “Given the projected deceleration in revenue growth from 59% in 2025 to 15-24% in 2026, what are the key drivers for re-accelerating growth beyond 2026, particularly in new specialties and international markets?”

  • 3

    “With the $1 billion in convertible senior notes due in 2030, how does the company plan to manage potential future dilution for common shareholders, and what is the anticipated timeline for a significant liquidity event for employees?”

Community

Valuation Sentiment

Our model estimates +8% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.